Can cancer patients get their infusions in less time? new study aims to find out

NCT ID NCT06031233

Recruiting now Symptom relief Sponsor: Isala Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing whether giving several common cancer immunotherapy drugs over a shorter time is safe. It involves 776 adults starting treatment with drugs like nivolumab or pembrolizumab. Infusion times will be gradually shortened if patients tolerate it well, and researchers will monitor for infusion reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, pembrolizumab, ipilimumab, durvalumab, atezolizumab, bevacizumab, trastuzumab, rituximab
What this could lead to: If successful, this could allow cancer patients to receive their immunotherapy infusions in a shorter time, making treatment more convenient.
What could go wrong: This is an early-phase observational study, so results may not apply to all patients. There is a risk of infusion reactions with faster delivery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFUSION REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFUSION REACTION ONCOLOGY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Isala Hospital
RECRUITING

Zwolle, 8025AB, Netherlands

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.